MedTrace Logo

Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients

NCT06556134 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-08-15

No results posted yet for this study

Summary

This study aims to assess the comparative effects of intravenous and liposomal oral iron on hemoglobin levels in non-dialysis CKD patients. Additionally, it seeks to evaluate the rate of hemoglobin correction, iron reserve status during treatment, and therapeutic tolerance to these interventions.

Conditions

  • Anemia of Chronic Kidney Disease

Interventions

DRUG

Intravenous Iron Sucrose

Intravenous iron-hydroxide sucrose complex administered in a dose of 100 mg, diluted in 250 mL of normal saline, and infused weekly for a period of 3 months

DRUG

Oral Iron

One oral capsule per day, containing 30 mg of pyrophosphate liposomal iron and 70 mg of ascorbic acid

Sponsors & Collaborators

  • Centre Hospitalier Hassan II - Fès

    lead OTHER

Principal Investigators

  • Tariq Sqalli Houssaini, MD · Laboratory of Epidemiology and Health Science Research, Sidi Mohammed Ben Abdellah University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-07-01
Completion
2024-01-10

Countries

  • Morocco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06556134 on ClinicalTrials.gov